YOLFTbeta
Neurizon Therapeutics Ltd

Neurizon Therapeutics Ltd

NUZ · AU · Healthcare / Biotechnology

0.058AUD+0.00 (+1.75%)

Price History

Full chart

Market Stats

Previous Close0.057
Open0.059
Day Range0.058 – 0.059
52-Week Range0.053 – 0.1475
Volume1.13M
Market Cap69.67M
P/E (TTM)0.00
Forward P/E5.33
EPS-0.02
Dividend Yield0.00%
Beta1.20
50-Day Avg0.0671
200-Day Avg0.0755

About

Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. John Clark
  • Employees0
  • Headquarters385 Bourke Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.neurizon.com

Leadership

  • Mr. John ClarkChief Operating Officer
  • Dr. Gary PittHead of Chemistry
  • Dr. James RixsonHead of Production
  • Dr. Herbert BrinkmanHead of Manufacturing
  • Ms. Lidija DamjanovicHead of Market Engagement & Corporate Affairs
  • Dr. Chris Freitag M.D.Chief Medical Advisor · b. 1966
  • Dr. Martin EngelHead of Scientific & Commercial Partnerships
  • Mr. Stefan RossCompany Secretary
  • Ms. Fiona MilnerGeneral Manager of Epichem Pty Ltd

Financials

Income Statement

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-311.15K311.15K3.21M6.11M6.11M2.70M1.56M1.76M1.64M1.55M1.62M1.88M1.87M1.87M2.85M2.87M3.67M3.20M3.20M3.38M3.38M873.65K--17.59M
Growth (%)--0.00%+931.95%+90.16%0.00%-55.84%-41.96%+12.19%-6.54%-5.39%+4.21%+16.26%-0.62%0.00%+52.69%+0.60%+27.83%-12.93%0.00%+5.80%0.00%-74.16%---
Cost of Revenue-35.20K35.20K3.50M6.93M1.84M3.09M3.09M193.72K209.46K142.31K176.64K222.67K207.78K207.78K340.62K289.32K289.32K333.63K3.62M314.34K3.60M3.75M1.64K-2.00K
Gross Profit-275.95K275.95K-288.60K-822.61K4.26M-390.95K-390.95K1.56M1.43M1.41M1.44M1.66M1.66M-103.17K2.51M2.58M-1.10M250.84K-424.02K3.07M-223.52K-929.53K-1.64K-17.59M
Gross Margin-88.69%88.69%-8.99%-13.47%69.85%-14.50%-24.98%88.97%87.23%90.83%89.08%88.16%88.88%-5.52%88.07%89.92%-29.93%7.85%-13.27%90.70%-6.61%-106.40%--100.00%
Operating Expense-4.00M2.25M994.69K2.49M7.58M4.82M2.27M2.18M2.07M2.25M5.67M3.10M4.13M2.45M4.28M5.50M1.82M2.45M1.75M5.82M2.53M5.73M6.66M-45.34M
Operating Income--3.72M-1.97M-1.28M-3.32M-3.32M-5.21M-2.66M-622.30K-633.77K-839.46K-4.23M-1.44M-2.47M-2.55M-1.76M-2.92M-2.92M-2.20M-2.17M-2.75M-2.75M-6.66M-6.66M-18.48M-27.76M
Operating Margin--1197.04%-634.48%-39.97%-54.30%-54.30%-193.34%-170.19%-35.45%-38.62%-54.07%-261.31%-76.64%-132.27%-136.56%-61.79%-101.62%-79.50%-68.76%-67.93%-81.30%-81.30%-762.16%---157.83%
EBITDA-1.84M-1.13M-2.33M-3.12M-2.26M-2.26M-3.78M1.41M22.49K-271.08K-5.73M-4.16M-661.19K-1.39M-3.78M-1.16M-1.64M-2.80M-2.03M-968.86K-1.30M-1.30M-9.45M-9.45M-18.48M-27.75M
EBITDA Margin--362.80%-748.97%-97.07%-36.95%-36.95%-140.35%90.25%1.28%-16.52%-368.98%-257.26%-35.15%-74.26%-202.12%-40.68%-57.13%-76.27%-63.36%-30.32%-38.59%-38.59%-1081.86%---157.82%
Net Income-2.09M-3.71M-2.07M36.86K-2.75M-2.75M-3.61M-179.60K-179.60K-438.60K-4.26M-4.26M-1.32M-1.93M-1.93M-1.34M-2.52M-2.52M-1.55M-1.36M-1.71M-1.71M-9.03M-9.03M-16.59M-10.72M
Net Income Margin--1190.76%-666.29%1.15%-45.08%-45.08%-133.74%-11.48%-10.23%-26.73%-274.43%-263.34%-70.07%-102.99%-102.99%-47.08%-87.82%-68.70%-48.54%-42.62%-50.52%-50.52%-1033.86%---60.98%
R&D--53.25K53.25K---------211.64K702.04K329.30K463.88K1.04M605.35K605.35K554.14K758.65K1.03M3.85M11.68M21.05M
R&D as % of Total Revenue--17.11%1.66%---------11.32%37.56%11.54%16.16%28.31%18.94%18.94%16.39%22.44%118.09%--119.70%
Interest Expense266120.28K120.28K46.57K28.63K77.25K129.30K129.30K143.35K105.33K4.37K40.59K33.59K2.67K3.56K39.93K59.38K28.35K47.82K118.50K78.99K88.51K81.86K--737.25K
Interest Expense % of Total Revenue-38.66%38.66%1.45%0.47%1.27%4.80%8.26%8.17%6.42%0.28%2.51%1.79%0.14%0.19%1.40%2.07%0.77%1.50%3.71%2.34%2.62%9.37%--4.19%

Balance Sheet

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets4.99M4.93M2.51M904.88K5.27M9.17M7.99M7.57M7.57M1.45M1.45M2.41M8.21M9.52M6.26M8.20M8.36M8.36M10.75M10.95M10.08M6.13M6.13M11.12M4.36M23.70M
Total Liabilities979.80K1.46M163.86K163.86K1.41M1.48M2.33M2.08M1.02M1.02M302.95K1.20M445.48K683.22K1.23M1.28M1.22M1.14M2.22M2.22M2.07M2.23M2.24M896.61K1.54M10.97M
Total Equity4.01M3.47M658.88K3.87M7.69M7.69M5.91M5.91M5.86M5.81M1.15M1.21M310.88K8.84M8.84M5.02M6.92M7.14M7.46M8.53M8.88M7.84M3.89M10.23M2.82M12.73M
Cash1.91M930.00K624.36K182.29K784.99K328.83K817.36K3.80M3.80M2.75M122.91K122.91K2.30M2.30M3.41M881.82K2.59M1.88M2.09M2.88M3.02M2.42M2.71M9.71M4.16M12.69M
Total Debt848.53K1.17M431.58K37.90K289.08K366.45K1.56M1.38M1.38M64.09K35.97K595.36K39.49K39.49K607.90K487.50K425.64K324.61K1.47M1.47M1.28M1.39M1.05M--3.31M
Net Debt-1.06M243.57K-144.38K-552.53K-495.91K37.62K741.23K-2.42M-2.42M-2.69M472.45K472.45K-2.26M-2.26M-273.92K-2.10M-2.16M-1.55M-618.77K-1.41M-1.74M-1.03M-1.66M-9.71M-4.16M-9.38M

Cash Flow

Currency: AUD2001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow---1.16M-1.82M-3.05M-3.05M-2.39M-2.39M-474.73K-1.45M-487.30K-305.46K-1.59M-1.59M-1.75M-1.60M-1.26M-1.55M-1.55M-1.27M-937.97K-1.33M-1.56M-5.17M-14.29M-15.07M
Investing Cash Flow-1.22M-869.00K-278.91K-3.76M-616.29K-616.29K-156.75K-157.00K294.68K-1.85M-310.67K12.79K299.41K299.41K-109.73K-1.50M-57.02K-868.93K-146.72K-30.23K-138.04K-43.38K-34.93K-1.17M-21.55K-8.22K
Financing Cash Flow6.39M2.94M999.07K6.03M3.36M3.21M3.10M3.10M-867.72K631.64K834.71K532.64K3.23M3.23M2.97M569.65K3.02M1.70M1.92M2.09M1.22M770.99K1.89M13.34M8.76M23.51M
Capital Expenditure689.08K53.00K368.56K3.50M275.61K351.98K156.74K41.75K42.88K10.92K4.41K11.50K81.36K73.30K109.73K1.50M57.02K868.93K146.72K30.23K138.04K43.38K34.93K31.54K8.22K
Free Cash Flow-689.08K-53.00K-1.53M-5.32M-3.33M-4.86M-2.55M-814.01K-517.61K-1.46M-491.71K-316.96K-386.82K-1.66M-1.86M-3.10M-1.31M-2.42M-1.70M-1.30M-1.08M-1.38M-1.60M-5.17M-14.29M-15.08M
FCF to OCF--131.71%292.18%109.04%159.41%106.55%34.01%109.03%100.75%100.91%103.76%24.35%104.62%106.27%193.74%104.54%156.03%109.44%102.38%114.72%103.26%102.23%100.00%100.01%100.05%

Earnings

Report DateFeb 29, 2016Aug 31, 2016Feb 28, 2017Sep 1, 2017Feb 28, 2018Sep 2, 2018Feb 28, 2019Aug 30, 2019Feb 28, 2020Aug 31, 2020Feb 26, 2021Aug 18, 2021Feb 18, 2022Aug 26, 2022Feb 27, 2023Feb 17, 2025Aug 25, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.020.000.00-0.01-0.01-0.010.00-0.010.000.000.000.000.000.000.00-0.02-0.02
Surprise-----------------
Timing-----------------

Key Statistics & Ratios

Market Cap69.67M
Enterprise Value54.65M
Trailing P/E0.00
Forward P/E5.33
PEG Ratio0.76
Price / Sales3.96
Price / Book4.79
EPS-0.02
Book Value0.017
Revenue (TTM)17.59M
Gross Profit (TTM)17.59M
EBITDA-10.17M
Profit Margin-60.98%
Operating Margin-40.78%
Return on Equity-137.94%
Return on Assets-45.31%
Shares Outstanding791.65M
Shares Float594.47M
Beta1.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 29, 20151:20
  • Nov 14, 20041:5